The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Northwestern Medicine scientists have identified a key driver of chemotherapy resistance in advanced ovarian cancer, ...

The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 ...

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...

The FDA has granted fast track designation to INX-315 for the treatment of CCNE1-amplified, platinum-resistant/refractory ovarian cancer.

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Fast Track designation highlights potential of INX-315 to address unmet need for patients with recurrent advanced/metastatic ...

Elahere is the first drug to improve survival in platinum-resistant ovarian cancer. "Ovarian cancer can be devastating and, when cancer cells stop responding to chemotherapy, patients may feel ...